tiprankstipranks
Design Therapeutics (DSGN)
NASDAQ:DSGN
US Market
DSGN
Design Therapeutics
RESEARCH TOOLSreports
Want to see DSGN full AI Analyst Report?

Design Therapeutics (DSGN) Stock Forecast & Price Target

107 Followers
See the Price Targets and Ratings of:

DSGN Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Design
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DSGN Stock 12 Month Forecast

Average Price Target

$20.75
▲(132.10% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Design Therapeutics in the last 3 months. The average price target is $20.75 with a high forecast of $22.00 and a low forecast of $20.00. The average price target represents a 132.10% change from the last price of $8.94.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","23":"$23","7.25":"$7.25","12.5":"$12.5","17.75":"$17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,7.25,12.5,17.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.66,15.224615384615385,15.78923076923077,16.353846153846153,16.91846153846154,17.483076923076922,18.04769230769231,18.61230769230769,19.176923076923078,19.74153846153846,20.306153846153848,20.87076923076923,21.435384615384613,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.66,15.128461538461538,15.596923076923076,16.065384615384616,16.533846153846152,17.002307692307692,17.470769230769232,17.939230769230768,18.407692307692308,18.876153846153848,19.344615384615384,19.813076923076924,20.28153846153846,{"y":20.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.66,15.070769230769232,15.481538461538461,15.892307692307693,16.303076923076922,16.713846153846156,17.124615384615385,17.535384615384615,17.946153846153848,18.356923076923078,18.767692307692307,19.17846153846154,19.58923076923077,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.38,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.41,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.23,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.44,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$22.00Average Price Target$20.75Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on DSGN
Kostas Biliouris
Oppenheimer
Oppenheimer
$21
Buy
134.90%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)
Piper Sandler Analyst forecast on DSGN
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$20
Buy
123.71%
Upside
Reiterated
05/27/26
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)
Craig-Hallum Analyst forecast on DSGN
Adam Vogel
Craig-Hallum
Craig-Hallum
$22
Buy
146.09%
Upside
Assigned
05/19/26
Analysts' Top Healthcare Picks: Neuren Pharmaceuticals Limited (NURPF), Design Therapeutics (DSGN)
RBC Capital Analyst forecast on DSGN
Leonid Timashev
RBC Capital
RBC Capital
$14→$20
Buy
123.71%
Upside
Reiterated
05/18/26
Analysts Conflicted on These Healthcare Names: Design Therapeutics (NASDAQ: DSGN), Pro Medicus Limited (Other OTC: PMCUF) and Boston Scientific (NYSE: BSX)
Cantor Fitzgerald Analyst forecast on DSGN
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
―
Buy
―
Initiated
05/12/26
Design Therapeutics initiated with an Overweight at Cantor FitzgeraldDesign Therapeutics initiated with an Overweight at Cantor Fitzgerald
Jefferies Analyst forecast on DSGN
Faisal Khurshid
Jefferies
Jefferies
$10.01→$15
Buy
67.79%
Upside
Initiated
03/15/26
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst
Leerink Partners Analyst forecast on DSGN
Joseph Schwartz
Leerink Partners
Leerink Partners
$14
Buy
56.60%
Upside
Upgraded
12/03/25
Design Therapeutics upgraded to Outperform from Market Perform at LeerinkDesign Therapeutics upgraded to Outperform from Market Perform at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on DSGN
Kostas Biliouris
Oppenheimer
Oppenheimer
$21
Buy
134.90%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)
Piper Sandler Analyst forecast on DSGN
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$20
Buy
123.71%
Upside
Reiterated
05/27/26
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)
Craig-Hallum Analyst forecast on DSGN
Adam Vogel
Craig-Hallum
Craig-Hallum
$22
Buy
146.09%
Upside
Assigned
05/19/26
Analysts' Top Healthcare Picks: Neuren Pharmaceuticals Limited (NURPF), Design Therapeutics (DSGN)
RBC Capital Analyst forecast on DSGN
Leonid Timashev
RBC Capital
RBC Capital
$14→$20
Buy
123.71%
Upside
Reiterated
05/18/26
Analysts Conflicted on These Healthcare Names: Design Therapeutics (NASDAQ: DSGN), Pro Medicus Limited (Other OTC: PMCUF) and Boston Scientific (NYSE: BSX)
Cantor Fitzgerald Analyst forecast on DSGN
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
―
Buy
―
Initiated
05/12/26
Design Therapeutics initiated with an Overweight at Cantor FitzgeraldDesign Therapeutics initiated with an Overweight at Cantor Fitzgerald
Jefferies Analyst forecast on DSGN
Faisal Khurshid
Jefferies
Jefferies
$10.01→$15
Buy
67.79%
Upside
Initiated
03/15/26
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst
Leerink Partners Analyst forecast on DSGN
Joseph Schwartz
Leerink Partners
Leerink Partners
$14
Buy
56.60%
Upside
Upgraded
12/03/25
Design Therapeutics upgraded to Outperform from Market Perform at LeerinkDesign Therapeutics upgraded to Outperform from Market Perform at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Design Therapeutics

3 Months
Leonid TimashevRBC Capital
Success Rate
6/10 ratings generated profit
60%
Average Return
+2.73%
Copying Leonid Timashev's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.73% per trade.
1 Year
Leonid TimashevRBC Capital
Success Rate
4/10 ratings generated profit
40%
Average Return
-23.62%
Copying Leonid Timashev's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -23.62% per trade.
2 Years
Leonid TimashevRBC Capital
Success Rate
4/10 ratings generated profit
40%
Average Return
-29.78%
Copying Leonid Timashev's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -29.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DSGN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
2
6
5
5
Buy
2
5
6
4
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
7
12
9
6
In the current month, DSGN has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DSGN average Analyst price target in the past 3 months is 20.75.
Each month's total comprises the sum of three months' worth of ratings.

DSGN Financial Forecast

DSGN Earnings Forecast

Next quarter’s earnings estimate for DSGN is -$0.34 with a range of -$0.46 to -$0.29. The previous quarter’s EPS was -$0.29. DSGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DSGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for DSGN is -$0.34 with a range of -$0.46 to -$0.29. The previous quarter’s EPS was -$0.29. DSGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DSGN has Performed in-line its overall industry.
No data currently available

DSGN Sales Forecast

Next quarter’s sales forecast for DSGN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DSGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DSGN has Performed in-line its overall industry.
Next quarter’s sales forecast for DSGN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DSGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DSGN has Performed in-line its overall industry.

DSGN Stock Forecast FAQ

What is DSGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Design Therapeutics’s 12-month average price target is 20.75.
    What is DSGN’s upside potential, based on the analysts’ average price target?
    Design Therapeutics has 132.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DSGN a Buy, Sell or Hold?
          Design Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Design Therapeutics’s price target?
            The average price target for Design Therapeutics is 20.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $22.00 ,the lowest forecast is $20.00. The average price target represents 132.10% Increase from the current price of $8.94.
              What do analysts say about Design Therapeutics?
              Design Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of DSGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.